Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $968.90M. Across the group, the median move over the past trading day is +4.71%. Price change over the past year runs from −1.4% to +452.8% across the middle 80 percent of the group, with a median of +233.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| BLFS | BioLife Solutions, Inc. | $1.82B | Small cap | +45.11% |
| IMMX | Immix Biopharma, Inc. | $968.90M | Small cap | +589.05% |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $501.00M | Small cap | +248.46% |
| 219A.T | HEARTSEED INC | $338.82M | Small cap | −32.33% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.